Ruhi Khan Biography and Net Worth

Insider of Caribou Biosciences

Ruhi serves as chief business officer for Caribou Biosciences, responsible for developing and executing on business development strategy. She brings over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. Most recently, Ruhi was the founder of an advisory firm that provided business development and finance advice to life sciences companies. In this role she had extensive senior management experience as head of business development for several oncology-focused companies. Previously, Ruhi was the head and vice president of business development for Acorda Therapeutics, Inc. Prior to Acorda, she worked in a similar capacity at Lexicon Pharmaceuticals, Inc. She started her career in venture capital with Fidelity Biosciences Group (now F-Prime Capital) and MPM Capital Advisors. Ruhi holds an MBA in health care management from The Wharton School, University of Pennsylvania, and an AB in biology from Harvard College.

What is Ruhi Ahmad Khan's net worth?: The estimated net worth of Ruhi Ahmad Khan is at least $168.52 thousand as of February 24th, 2026. Khan owns 104,998 shares of Caribou Biosciences stock worth more than $168,522 as of August 6th. This net worth estimate does not reflect any other investments that Khan may own. Learn More about Ruhi Ahmad Khan's net worth.
How do I contact Ruhi Ahmad Khan?: The corporate mailing address for Khan and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Ruhi Ahmad Khan's contact information.
Has Ruhi Ahmad Khan been buying or selling shares of Caribou Biosciences?: Ruhi Ahmad Khan has not been actively trading shares of Caribou Biosciences during the last ninety days. Most recently, Ruhi Ahmad Khan sold 6,938 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $1.96, for a transaction totalling $13,598.48. Following the completion of the sale, the insider now directly owns 104,998 shares of the company's stock, valued at $205,796.08. Learn More on Ruhi Ahmad Khan's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Tina Albertson (Insider), Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Rachel Haurwitz (CEO), Steven Kanner (Insider), Timothy Kelly (CTO), Ruhi Khan (Insider), Barbara McClung (Insider), and Sriram Ryali (CFO). Learn More on Caribou Biosciences' active insiders.
Are insiders buying or selling shares of Caribou Biosciences?: During the last year, insiders at the sold shares 4 times. They sold a total of 18,089 shares worth more than $35,454.44. The most recent insider tranaction occured on February, 24th when CTO Timothy P Kelly sold 3,147 shares worth more than $6,168.12. Insiders at Caribou Biosciences own 8.5% of the company. Learn More about insider trades at Caribou Biosciences.
Information on this page was last updated on 2/24/2026.

Ruhi Ahmad Khan Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/24/2026	Sell	6,938	$1.96	$13,598.48	104,998

Ruhi Ahmad Khan Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $1.62

$1.59

$1.68

50 Day Range

MA: $1.76

$1.46

$2.43

2 Week Range

Now: $1.62

$1.38

$3.54

Volume

444,772 shs

Average Volume

1,579,234 shs

Market Capitalization

$160.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38